Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep 27;16(19):3293.
doi: 10.3390/cancers16193293.

A Comprehensive Review of the Antitumor Properties and Mechanistic Insights of Duocarmycin Analogs

Ann Morcos  1   2 , Yeonkyu Jung  1   2 , Joab Galvan Bustillos  1   2   3 , Ryan N Fuller  1   2 , David Caba Molina  3 , Antonella Bertucci  1   4 , Kristopher E Boyle  5 , Marcelo E Vazquez  1   6 , Nathan R Wall  1   2
Affiliations
Review

A Comprehensive Review of the Antitumor Properties and Mechanistic Insights of Duocarmycin Analogs

Ann Morcos et al. Cancers (Basel). .

Abstract

The duocarmycin family is a group of potent cytotoxic agents originally isolated from the bacterium Streptomyces. This discovery has spurred significant interest due to duocarmycins' unique chemical structures and powerful mechanism of action. This review comprehensively details the history of the duocarmycin family, the current understanding of their therapeutic potential, and the major clinical trials that have been conducted. Chemically, the duocarmycin family is characterized by a DNA-binding unit that confers specificity, a subunit-linking amide that positions the molecule within the DNA helix, and an alkylating unit that interacts with the DNA. This configuration allows them to bind selectively to the minor groove of DNA and alkylate adenine bases, a notable deviation from the more common guanine targeting performed by other alkylating agents. Duocarmycin's mechanism of action involves the formation of covalent adducts with DNA, leading to the disruption of the DNA architecture and subsequent inhibition of replication and transcription. Recent advancements in drug delivery systems, such as antibody-drug conjugates (ADCs), have further elevated the therapeutic prospects of duocarmycin analogs by providing a promising mechanism for enhancing intracellular concentrations and selective tumor delivery. Preclinical studies have highlighted the efficacy of duocarmycin derivatives in various in vitro models, providing a strong foundation for translational research. However, further biological research is required to fully understand the toxicology of duocarmycin family members before it can be clinically relevant. The major focus of this review is to cache the major biologically relevant findings of different duocarmycin analogs as well as their biological shortcomings to propose next steps in the field of cancer therapy with these potent therapeutics.

Keywords: cellular mechanisms; duocarmycin; potency; resistance; seco-DSA.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Chemical structures of DSA and its analogs.
Figure 2
Figure 2
Schematic of DSA-binding and alkylation mechanism. Adapted from Sakata et al. 2019 [33].
Figure 3
Figure 3
Duocarmycin derivatives. Adapted from Puyo et al. 2014 [35].
See this image and copyright information in PMC

References

    1. Felber J.G., Thorn-Seshold O. 40 Years of Duocarmycins: A Graphical Structure/Function Review of Their Chemical Evolution, from SAR to Prodrugs and ADCs. JACS Au. 2022;2:2636–2644. doi: 10.1021/jacsau.2c00448. - DOI - PMC - PubMed
    1. Nani R.R., Gorka A.P., Nagaya T., Yamamoto T., Ivanic J., Kobayashi H., Schnermann M.J. In Vivo Activation of Duocarmycin-Antibody Conjugates by Near-Infrared Light. ACS Cent. Sci. 2017;3:329–337. doi: 10.1021/acscentsci.7b00026. - DOI - PMC - PubMed
    1. MacMillan K.S., Nguyen T., Hwang I., Boger D.L. Total synthesis and evaluation of iso-duocarmycin SA and iso-yatakemycin. J. Am. Chem. Soc. 2009;131:1187–1194. doi: 10.1021/ja808108q. - DOI - PMC - PubMed
    1. Yao H.P., Zhao H., Hudson R., Tong X.M., Wang M.H. Duocarmycin-based antibody-drug conjugates as an emerging biotherapeutic entity for targeted cancer therapy: Pharmaceutical strategy and clinical progress. Drug Discov. Today. 2021;26:1857–1874. doi: 10.1016/j.drudis.2021.06.012. - DOI - PubMed
    1. Boyle K.E., Boger D.L., Wroe A., Vazquez M. Duocarmycin SA, a potent antitumor antibiotic, sensitizes glioblastoma cells to proton radiation. Bioorganic Med. Chem. Lett. 2018;28:2688–2692. doi: 10.1016/j.bmcl.2018.04.008. - DOI - PMC - PubMed